"
Team:Paris Bettencourt/Human Practice/Safety
From 2013.igem.org
Zmarinkovic (Talk | contribs) |
Zmarinkovic (Talk | contribs) |
||
| Line 5: | Line 5: | ||
<h2> Risks to the safety and health of team members or others working in the lab </h2> | <h2> Risks to the safety and health of team members or others working in the lab </h2> | ||
| - | <p> | + | <p><b>Silencing antibiotic resistance:</b> |
| + | This system includes a phage designed to spread in an <i>E. coli</i> population. If it was | ||
| + | ingested by someone the phage could spread into the population of <i>E. coli</i> located in the gut. The | ||
| + | modifications to our phage, for example GFP expression, are likely to reduce fitness and would | ||
| + | facilitate diagnosis. We believe this risk to be comparable to that of other research on commonly | ||
| + | used coliphage.</p> | ||
| + | |||
| + | <p><b>Detecting antibiotic resistance:</b> | ||
| + | As above, this system uses a coliphage that could in principle spread in human gut fauna. This | ||
| + | system also uses CRISPR elements, which are relatively new to science and may present unknown | ||
| + | risks. We do not believe that our modifications will increase the risks above that of other | ||
| + | research on commonly used coliphage.</p> | ||
| + | |||
| + | <p><b>Eliminating Mycobacteria:</b> | ||
| + | This project employs the Lysteriolysin gene LLO derived from <i>Lysteria monocytogenes</i>. This gene | ||
| + | contributes the virulence of this pathogen. Although this gene is widely used in Biosafety Level 1 | ||
| + | facilities, the precautionary principle applies. We will assume that this gene could enhance the | ||
| + | pathogenicity of <i>E. coli</i> or other bacteria, for example by allowing them to evade phagocytosis in | ||
| + | the human immune system.</p> | ||
| + | |||
| + | <p><b>Screening for sulfur metabolism inhibitors:</b> | ||
| + | For this project we will express in <i>E. coli</i> three genes from the sulfur assimilation | ||
| + | pathway of <i>Mycobacterium smegmatis</i>. We selected genes from this organism | ||
| + | because it is a non-pathogenic model for <i>M. tuberculosis</i>. To our knowledge, sulfur | ||
| + | metabolism does not enhance the pathogenicity of any known bacterial species. | ||
| + | Therefore we believe this project to carry risks not exceeding those of standard lab | ||
| + | work with <i>E. coli</i>.</p> | ||
<br> | <br> | ||
Revision as of 20:56, 3 October 2013
<body>
Risks to the safety and health of team members or others working in the lab
Silencing antibiotic resistance: This system includes a phage designed to spread in an E. coli population. If it was ingested by someone the phage could spread into the population of E. coli located in the gut. The modifications to our phage, for example GFP expression, are likely to reduce fitness and would facilitate diagnosis. We believe this risk to be comparable to that of other research on commonly used coliphage.
Detecting antibiotic resistance: As above, this system uses a coliphage that could in principle spread in human gut fauna. This system also uses CRISPR elements, which are relatively new to science and may present unknown risks. We do not believe that our modifications will increase the risks above that of other research on commonly used coliphage.
Eliminating Mycobacteria: This project employs the Lysteriolysin gene LLO derived from Lysteria monocytogenes. This gene contributes the virulence of this pathogen. Although this gene is widely used in Biosafety Level 1 facilities, the precautionary principle applies. We will assume that this gene could enhance the pathogenicity of E. coli or other bacteria, for example by allowing them to evade phagocytosis in the human immune system.
Screening for sulfur metabolism inhibitors: For this project we will express in E. coli three genes from the sulfur assimilation pathway of Mycobacterium smegmatis. We selected genes from this organism because it is a non-pathogenic model for M. tuberculosis. To our knowledge, sulfur metabolism does not enhance the pathogenicity of any known bacterial species. Therefore we believe this project to carry risks not exceeding those of standard lab work with E. coli.
fqa
foo
fqa
foo
fqa
foo
fqa
foo
fqa
foo
fqa
foo
fqa
foo
fqa
foo
fqa
foo
fqa
foo
fqa
foo
fqa
foo
fqa
foo
fqa
foo
fqa
foo
fqa
foo
fqa
foo
fqa
foo
fqa
foo
fqa
foo
fqa
foo
fqa
foo
fqa
foo
fqa
foo
fqa
foo
fqa
foo
fqa
foo
fqa
foo
fqa
foo
fqa
foo
fqa
foo
fqa
foo
fqa
foo
fqa
foo
fqa
foo
+33 1 44 41 25 22/25
team2013@igem-paris.org 
